Stella Pharma Corporation (TYO:4888)

Market Cap	14.89B +20.8%
Revenue (ttm)	323.00M -67.4%
Net Income	-852.00M
EPS	-24.87
Shares Out	37.03M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	573,700
Open	401.00
Previous Close	402.00
Day's Range	392.00 - 428.00
52-Week Range	200.00 - 995.00
Beta	0.29
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 6, 2026

About Stella Pharma

Stella Pharma Corporation engages in research and development, manufacturing, and distribution of pharmaceuticals. The company develops drugs for boron neutron capture therapy (BNCT). Its products include SPM-011, a boron-containing drug for BNCT used for treating head and neck cancer, recurrent malignant glioma, meningioma, malignant melanoma and angiosarcoma, glioblastoma, and thoracic malignant tumor. Stella Pharma Corporation was incorporated in 2007 and is headquartered in Osaka, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 47
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4888

Financial Performance

In fiscal year 2026, Stella Pharma's revenue was 323.00 million, a decrease of -66.39% compared to the previous year's 961.00 million. Losses were -780.00 million, 457.1% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 16, 2026

Data Sources Report a data error